# BCL9L

> Mediated Wiki article. Canonical URL: https://mediated.wiki/source/BCL9L
> Markdown URL: https://mediated.wiki/source/BCL9L.md
> Source: https://en.wikipedia.org/wiki/BCL9L
> Source revision: 1213866109
> License: Creative Commons Attribution-ShareAlike 4.0 International (https://creativecommons.org/licenses/by-sa/4.0/)

**B-cell CLL/lymphoma 9 like** is a [protein](/source/Protein) that in humans is encoded by the BCL9L [gene](/source/Gene). [1]

## References

1. ["Entrez Gene: B-cell CLL/lymphoma 9 like"](https://www.ncbi.nlm.nih.gov/gene/283149). Retrieved 2017-10-31.

## Further reading

- Sampietro J, Dahlberg CL, Cho US, Hinds TR, Kimelman D, Xu W (2006). "Crystal structure of a beta-catenin/BCL9/Tcf4 complex". *Mol. Cell*. **24** (2): 293–300. [doi:10.1016/j.molcel.2006.09.001](https://doi.org/10.1016/j.molcel.2006.09.001). [PMID 17052462](https://pubmed.ncbi.nlm.nih.gov/17052462)
- Miller TC, Rutherford TJ, Johnson CM, Fiedler M, Bienz M (2010). "Allosteric remodelling of the histone H3 binding pocket in the Pygo2 PHD finger triggered by its binding to the B9L/BCL9 co-factor". *J. Mol. Biol.*. **401** (5): 969–84. [doi:10.1016/j.jmb.2010.07.007](https://doi.org/10.1016/j.jmb.2010.07.007). [PMC 2927781](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2927781). [PMID 20637214](https://pubmed.ncbi.nlm.nih.gov/20637214)
- Brembeck FH, Wiese M, Zatula N, Grigoryan T, Dai Y, Fritzmann J, Birchmeier W (2011). "BCL9-2 promotes early stages of intestinal tumor progression". *Gastroenterology*. **141** (4): 1359–70, 1370.e1–3. [doi:10.1053/j.gastro.2011.06.039](https://doi.org/10.1053/j.gastro.2011.06.039). [PMID 21703997](https://pubmed.ncbi.nlm.nih.gov/21703997)
- Matsuura K, Jigami T, Taniue K, Morishita Y, Adachi S, Senda T, Nonaka A, Aburatani H, Nakamura T, Akiyama T (2011). "Identification of a link between Wnt/β-catenin signalling and the cell fusion pathway". *Nat Commun*. **2**: 548. [Bibcode:2011NatCo...2..548M](https://ui.adsabs.harvard.edu/abs/2011NatCo...2..548M). [doi:10.1038/ncomms1551](https://doi.org/10.1038/ncomms1551). [PMID 22109522](https://pubmed.ncbi.nlm.nih.gov/22109522)
- Zatula N, Wiese M, Bunzendahl J, Birchmeier W, Perske C, Bleckmann A, Brembeck FH (2014). "The BCL9-2 proto-oncogene governs estrogen receptor alpha expression in breast tumorigenesis". *Oncotarget*. **5** (16): 6770–87. [doi:10.18632/oncotarget.2252](https://doi.org/10.18632/oncotarget.2252). [PMC 4196162](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196162). [PMID 25149534](https://pubmed.ncbi.nlm.nih.gov/25149534)
- El-Hage P, Petitalot A, Monsoro-Burq AH, Maczkowiak F, Driouch K, Formstecher E, Camonis J, Sabbah M, Bièche I, Lidereau R, Lallemand F (2015). "The Tumor-Suppressor WWOX and HDAC3 Inhibit the Transcriptional Activity of the β-Catenin Coactivator BCL9-2 in Breast Cancer Cells". *Mol. Cancer Res.*. **13** (5): 902–12. [doi:10.1158/1541-7786.MCR-14-0180](https://doi.org/10.1158/1541-7786.MCR-14-0180). [PMID 25678599](https://pubmed.ncbi.nlm.nih.gov/25678599)

---
Adapted from the Wikipedia article [BCL9L](https://en.wikipedia.org/wiki/BCL9L) by Wikipedia contributors ([contributor history](https://en.wikipedia.org/wiki/BCL9L?action=history)). Available under [Creative Commons Attribution-ShareAlike 4.0 International](https://creativecommons.org/licenses/by-sa/4.0/). Changes may have been made.